Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Up 10%

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shares shot up 10% on Tuesday . The stock traded as high as $0.23 and last traded at $0.22, 1,203,113 shares were traded during trading. An increase of 9% from the average session volume of 1,100,914 shares. The stock had previously closed at $0.20.

Several research firms have recently weighed in on ATNM. Maxim Group set a $3.00 price objective on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 4th. Zacks Investment Research cut shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 4th. Finally, William Blair began coverage on shares of Actinium Pharmaceuticals in a report on Thursday, August 8th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $3.56.

An institutional investor recently raised its position in Actinium Pharmaceuticals stock. Sio Capital Management LLC boosted its stake in Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 1,352.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,935,250 shares of the biotechnology company’s stock after purchasing an additional 4,595,454 shares during the quarter. Sio Capital Management LLC owned about 3.05% of Actinium Pharmaceuticals worth $1,214,000 as of its most recent SEC filing.

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Further Reading: Technical Analysis of Stocks and What It Means

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with's FREE daily email newsletter.